---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-027842"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2023-08-07T23:59:59+00:00"
generated_at: "2026-06-12T04:13:53.467908+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Avalo Therapeutics increases ATM offering capacity to $50M from $9M

## Summary
- Amended Sales Agreement with Oppenheimer ups aggregate offering to $50,000,000.
- As of Aug 4, 2023, had sold ~$8.3M of common stock under prior $9.03M limit.
- Remaining capacity under amended agreement is approximately $41.7M.
- Shares sold via 'at the market' offering under existing registration statement.

## SEC filing metadata
- accession: 0001628280-23-027842
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2023-08-07T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000162828023027842/0001628280-23-027842-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000162828023027842/avtx-20230807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-027842
- JSON: https://secwatch.observer/filing/0001628280-23-027842.json
- Plain text: https://secwatch.observer/filing/0001628280-23-027842.txt

## Key facts
- Material Agreements
  Avalo Therapeutics, Inc. amended Amendment No. 1 to the Sales Agreement with Oppenheimer & Co. Inc. valued at up to $50,000,000 (effective 2023-08-07).
  - Action: amendment
  - Agreement: atm program
  - Counterparty: Oppenheimer & Co. Inc.
  - Value: up to $50,000,000
  - Effective: 2023-08-07
  source text: On August 7, 2023, the Company and Oppenheimer entered into Amendment No. 1 to the Sales Agreement (the “Amendment”, and together with the Sales Agreement, the “Amended Sales Agreement”) to provide for an increase in the aggregate offering amount under the Sales Agreement, such that as of August 7, 2023 under the Amended Sales Agreement, the Company may offer and sell additional shares of common stock having an aggregate offering price of up to $50,000,000
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534120/000162828023027842/0001628280-23-027842-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.